soquelitinib
soquelitinib: developed by 1 company · 3 clinical trials tracked.
soquelitinib evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could soquelitinib → CRVS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) Atopic Dermatitis; Peripheral T-Cell Lymphoma, Not Otherwise… | Phase 3 |
Clinical Trials (3)
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)
Primary endpoint: Percent change from baseline in Eczema Area and Severity Index (EASI) score at Week 12
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Primary endpoint: Progression-free survival
A Phase 1, Randomized, Blinded, Placebo-controlled, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of ITK Inhibitor Soquelitinib in Participants With Moderate to Severe Atopic Dermatitis
Primary endpoint: Incidence of adverse events, changes in laboratory values, vital signs, and electrocardiograms
Frequently asked questions
Who is developing soquelitinib?
soquelitinib is being developed by Corvus Pharmaceuticals, Inc..
How many clinical trials involve soquelitinib?
BioSniper tracks 3 clinical trials involving soquelitinib.